)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Mesoblast
Mesoblast (MSB) investor relations material
Mesoblast AGM 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.AGM 2026 summary9 Nov, 2026
Opening remarks and agenda
Vision centered on life-saving cellular therapies, efficient operations, motivated teams, and appropriate shareholder returns.
Financial performance review
FY2026 net revenue was US$115M in RYONCIL’s first full year after U.S. launch; gross profit on sales was US$110M, excluding amortization.
Secured a US$125M five-year non-dilutive credit facility, consolidating and retiring two higher-cost facilities.
Board and executive committee updates
Greg George appointed Interim COO as a search continues for a U.S.-based COO to support manufacturing scale-up and potential rexlemestrocel-L launches.
Eric Rose will focus as CMO on cardiopulmonary programs and step away from Board activities.
Jon Voigtman is expected to join the Board subject to shareholder approval; Bill Burns and Phil Krause will retire, with a search underway for directors with biopharma, manufacturing, and commercial expertise.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Mesoblast
- RYONCIL revenue grew 44% as cash spend fell 86%, alongside pivotal trial and FDA progress.MSB
Q1 2027 - $120M revenue, net loss halved, and pipeline progress set up double-digit growth.MSBH2 2026
- RyoncilⓇ net revenue reached US $115M for the year, with strong growth and future momentum expected.MSBQ4 2026 TU
- Ryoncil's commercial success funds a robust pipeline targeting major inflammatory diseases.MSBInvestor presentation
- Ryoncil® revenues hit US$30.3M, cash spend improved, and key clinical milestones were achieved.MSBQ3 2026 TU
- Ryoncil's U.S. launch drove $51.3M H1 revenue and improved net loss to $40.2M.MSBH1 2026
- FDA approves first MSC therapy for pediatric steroid-refractory GVHD, launch imminent.MSBFDA Announcement
- RyoncilⓇ launch drove 191% revenue growth, expanded coverage, and strengthened cash reserves.MSBH2 2025
- FDA approval and $161M raise drive imminent U.S. launch and late-stage pipeline progress.MSBH1 2025
Mesoblast
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Mesoblast Limited is an Australian biotechnology company that develops cellular medicines based on mesenchymal lineage cells. The company’s pipeline targets inflammatory and cardiovascular diseases, with therapies in various stages of clinical development. Its operations include research, regulatory affairs, and strategic licensing. Mesoblast Limited is headquartered in Melbourne, Australia, and its shares are listed on the ASX.